
    
      After giving their consent, subjects will undergo a screening visit to determine eligibility
      for study entry. After randomization, subjects will have administered medical device Iracross
      or Iraline. For subjects allocated to Iracross, medical device will be administered only at
      first visit and for subjects allocated to Iraline, medical device will be administered at
      visit 1, visit,2, visit 3 and optional for visit 4 and visit 5.
    
  